目的:研究CD133+细胞的干性鉴定和131I-CD133抗体在体内外对人肝癌CD133+-HepG2干细胞的抑制作用。方法:氯胺T法制备并鉴定131I-CD133抗体;免疫磁珠(magnetic-activated cell sorting,MACS)分选CD133+-HepG2细胞;流式细胞仪(flow cytometry,FCM)检测分选前后CD133表达率;体外克隆形成实验、成球实验和体内成瘤实验验证其干细胞特性;将分选出的CD133+细胞分组为CD133抗体、131I、131I-CD133抗体和131I+CD133抗体4个组,MTT法检测不同处理后不同组中CD133+细胞生长抑制率;成功构建人肝癌CD133+-HepG2移植瘤模型;随机分4组,1次/2 d给予尾静脉用药,共14次。4周后,处死小鼠,比较肿瘤的体积、质量、计算抑瘤率;HE染色观察肿瘤组织病理学改变。结果:131I-CD133抗体标记率为89.34%,放化纯度为98.21%。流式显示分选前后CD133表达率分别为(1.78±0.54)%和(98.46±0.97)%。成球实验、克隆形成实验和裸鼠成瘤实验显现CD133+细胞相对于CD133-细胞更具有干细胞特性。131I-CD133抗体治疗组体外对细胞抑制率及体内抑瘤率明显高于其余各实验组,差异具有统计学意义(P<0.05)。结论:131I-CD133抗体在体内外均能有效抑制人肝癌CD133+-HepG2细胞的生长。 OBJECTIVE: To study the dry identification of CD133 + cells and the inhibitory effect of 131I-CD133 on human hepatoma CD133 + -HepG2 stem cells in vitro and in vivo. Methods: 131I-CD133 antibody was prepared and identified by chloramine T method. CD133 + -HepG2 cells were sorted by magnetic-activated cell sorting (MACS). Flow cytometry (FCM) ; In vitro cloning formation experiments, into the ball experiments and in vivo tumorigenicity experiments to verify the characteristics of stem cells; the sorted CD133 cells were grouped into CD133 antibody, 131I, 131I-CD133 antibody and 131I + CD133 antibody 4 groups, MTT method to detect different After treatment, CD133 + cell growth inhibition rate in different groups was successfully established. The human hepatocellular carcinoma CD133 + -HepG2 xenograft model was successfully established. The rats were randomly divided into 4 groups and administered with tail vein once a day for 14 times. After 4 weeks, the mice were killed and the tumor volume and mass were compared to calculate the tumor inhibition rate. The histopathological changes of the tumor tissues were observed by HE staining. Results: The labeling rate of 131I-CD133 antibody was 89.34% and the radiochemical purity was 98.21%. The expression rates of CD133 before and after flow cytometry were (1.78 ± 0.54)% and (98.46 ± 0.97)%, respectively. Spheroid formation experiments, clonogenic experiments and nude mouse tumorigenic experiments showed that CD133 + cells have more stem cell properties than CD133- cells. The inhibition rate of 131I-CD133 antibody in vitro and in vivo inhibition rate were significantly higher than the other experimental groups, the difference was statistically significant (P <0.05). Conclusion: 131I-CD133 antibody can effectively inhibit the growth of human hepatoma CD133 + -HepG2 cells both in vitro and in vivo.